377 funds of long positions, suddenly plummeted!
And also two consecutive days down, market value evaporated 37 billion, the reason is unknown, investors panic!
As of April 8 closing, Huahai Pharmaceutical (20.34 +0.59%, shares) share price of 20.22 yuan / share, down 9.93%, the latest market value of 29.41 billion yuan.
In order to ease the panic, on the evening of April 8, Huahai Pharmaceutical issued five announcements in a row, including abnormal stock trading fluctuations, the sale of part of the equity participation in the company, a report on the advance performance of the first quarter of this year, and a snapshot of the 2020 results.
Five consecutive announcements to clear doubts
Huahai Pharmaceuticals responded that the company’s stock trading in April 6, 2021 to April 8, three consecutive trading days price deviation value accumulated to 20%, and the company does not exist involving the company to disclose but not disclose the significant matters.
So, is it poor performance or investment stepping on mines that caused this plunge? According to the latest announcement, Huahai Pharmaceutical recently transferred its 3.8597% stake in Hangzhou Duo Xi Biotechnology Co. Enterprise Management Partnership (Limited Partnership), the total amount of the transfer is 110 million yuan.
To further dispel doubts, the performance side, Huahai Pharmaceutical also made a one-time preview. According to preliminary calculations by the finance department, the company’s net profit attributable to shareholders of the listed company for the first quarter of 2021 is expected to be between 242 million yuan and 265 million yuan, an increase of approximately 10% to 20% compared to the same period of the previous year (statutory disclosure data). However, the Company’s net profit attributable to shareholders of the listed company for the first quarter of 2021, excluding non-recurring gains and losses, is expected to be between 148 million yuan and 168 million yuan, a decrease of approximately 15% to 25% compared to the same period of the previous year (legally disclosed data).
So, would it be last year’s performance situation that dragged down today’s share price? According to the latest results flash report announced tonight, after preliminary accounting, the company achieved operating revenue of 6.485 billion yuan in 2020, up 20.36% year-on-year, and achieved net profit attributable to shareholders of listed companies of 930 million yuan, up 63.24% year-on-year, including net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses of 816 million yuan, up 81.38% year-on-year.
Suffering from holding shares change face
Why the share price will not stop falling?
Analysts believe that, combined with the recent market holdings of the low phenomenon, Huahai Pharmaceuticals belongs to the “top flow fund love shares” ranks, especially well-known fund managers such as Liang Hao, Xie Zhiyu, Glenn, Cheng Zhou, etc. are holding positions in this drug company. Could it be that their collective flight triggered the stop?
Choice data shows that as of the end of 2020, the company was heavily held by 377 funds, with a combined position of 308 million shares, accounting for 21% of the total share capital. 2020 quarterly report shows that social security funds, investment funds and insurance funds are present in the list of the company’s top ten shareholders in circulation.
From the April 7 after-hours LW list data, the top five selling seats are clear institutional seats, the total selling amount of 267 million yuan. And buying seats, but no one institutional seats. Combined with the two days of after-hours data, the top five sellers are institutional seats. April 7 – April 8, a total of nearly 900 million yuan sold.
Looking at the company’s share price trend in the past year, it peaked at the end of August 2020, touching 45.7 yuan per share intraday. However, since August 31, 2020, the company’s share price has retreated all the way to the present, and has fallen 54% in total during the period. In the last month, the company’s share price has averaged at $24 per share.
Recent Comments